Navigation Links
Metamark Genetics, Inc. Announces New Chief Executive Officer
Date:11/5/2010

CAMBRIDGE, Mass., Nov. 5, 2010 /PRNewswire/ -- Metamark Genetics, Inc., a privately held oncology molecular diagnostics company, announced today the appointment of Mark R. Straley as the company's President, Chief Executive Officer, and newest member of its Board of Directors. Kenneth E. Weg, a Metamark co-founder who previously served as interim CEO, will continue to serve as Chairman of the Board of Directors.

Mr. Straley brings twenty five years of experience to Metamark Genetics, Inc., as a proven General Manager with Sales and Marketing expertise in the Global Healthcare Industry. With particular focus on the Diagnostics and Diabetes markets, Mark has a demonstrated track record of increasing revenue and profitability. With both Fortune 100 company and start-up expertise, Mark has operated in multiple healthcare sectors in both developed and emerging markets.

Most recently, Mark was the Worldwide President of Johnson & Johnson's Diagnostics division accountable for $2B in revenue with global responsibility for sales, marketing, customer support and commercial operations. Mark joined Johnson & Johnson in 2005 as the Global Vice President of Marketing for the Diagnostics division. Prior to his assignment with J&J, Mr. Straley worked for such brand name companies as Bayer Healthcare and Abbott Laboratories where he held progressively responsible roles in sales, marketing and general management in several North American locations. Mark is a graduate of Miami University located in Oxford, Ohio with a Bachelor of Science in Marketing.

Kenneth E. Weg, Metamark's Chairman, stated, "Metamark is extremely fortunate to have attracted such a seasoned and successful diagnostics executive to serve as Chief Executive Officer. On behalf of the entire Company and Board of Directors, I welcome Mark to the team and look forward to his leadership."

When commenting on his decision to join Metamark, Mr. Straley stated, "There remains a significant unmet medical need among patients diagnosed with early-stage cancers and their physicians when considering the selection of the most appropriate treatment for that individual patient's tumor. The mission of Metamark is to empower personalized treatment decisions through innovative assays that report on the fundamental molecular determinants of metastatic risk. It is a rare opportunity to be able to join Metamark's team of world-renowned scientific and business leaders in pursuit of this mission."

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Scientific Officer
2. Interleukin Genetics, Inc. Receives Delisting Notification from NYSE Amex
3. deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court
4. Matching Genetics, Technology and Management Practices Critical to Meeting Strong Demand for Agricultural Crops
5. Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants
6. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
7. IGEN NETWORKS ANNOUNCES THE APPOINTMENT OF TWO NEW MEMBERS TO THE ADVISORY BOARD
8. Elsevier Announces New Partnership With Canadian Cardiovascular Society to Publish the Canadian Journal of Cardiology
9. Advanced Life Sciences Announces US Army Collaboration to Research and Develop Restanza for the Treatment of Malaria
10. QuantaLife Announces Launch of Droplet Digital™ PCR System
11. diaDexus Announces Name Change From VaxGen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 ... new report "Nanobiotechnology Applications, Markets and Companies" to ... , ... of nanobiotechnology by the pharmaceutical and biotechnology industries is anticipated. ... - from formulations for optimal delivery to diagnostic applications in ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... Computational Science Symposium (CSS) and the popularity of US Single Day Events (SDE) ... place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and ...
(Date:12/2/2016)... , ... December 02, 2016 ... ... a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved ... interested in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:12/2/2016)... leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI HIV ... http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton Health ... Self Test to 350 pharmacy representatives in Nairobi and Mombasa, ...
Breaking Biology Technology:
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
Breaking Biology News(10 mins):